<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268619</url>
  </required_header>
  <id_info>
    <org_study_id>HOE498_3501</org_study_id>
    <nct_id>NCT00268619</nct_id>
  </id_info>
  <brief_title>FOCUS:Focus On Coronary Unstable Syndromes</brief_title>
  <official_title>A Placebo-controlled, Double-blind, Randomized, Multicenter Study of Ramipril 5 and 10 mg Capsules and Insulin Infusion in Subjects With Unstable Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study objectives:&#xD;
&#xD;
        -  To demonstrate that the acute administration of ramipril will control the inflammation&#xD;
           process in patients with high-risk Acute Coronary Syndrome (ACS) as assessed by the high&#xD;
           sensitivity C-reactive protein blood levels.&#xD;
&#xD;
        -  To demonstrate that the normalization of blood glucose levels with intravenous insulin&#xD;
           will improve the inflammation process during the acute phase of an ACS as assessed by&#xD;
           Tumor necrosis factor alpha blood levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the highly specific C-reactive protein (hsCRP) blood levels</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the tumor necrosing factor alpha (TNFÎ±) blood levels</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TEAEs collection</measure>
    <time_frame>From the signature of the informed consent up to the end of the study</time_frame>
  </secondary_outcome>
  <condition>Myocardial Ischemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject either not of childbearing potential or is not pregnant and agrees to use&#xD;
             contraceptive measure for the duration of the study&#xD;
&#xD;
          -  Subjects presenting within 12 hours after the last episode of chest pain with:&#xD;
&#xD;
               -  An accelerating pattern of anginal pain&#xD;
&#xD;
               -  A prolonged or recurrent anginal pain at rest or with minimal effort AND&#xD;
&#xD;
               -  Evidence of myocardial ischemia on ECG manifested by at least one of the&#xD;
                  following ECG criteria: - new persistent or transient ST-segment depression OR&#xD;
                  transient or reversible ST-segment elevation or new persistent or transient&#xD;
                  T-wave inversion OR Abnormal cardiac markers defined as: CK-MB greater than the&#xD;
                  upper limit of normal Troponin T or I level greater than the upper limit of&#xD;
                  normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected pregnancy or actively breast-feeding&#xD;
&#xD;
          -  Female of childbearing potential not using or planning to use a reliable method of&#xD;
             contraception&#xD;
&#xD;
          -  Treatment with Hormone Replacement Therapy at time of randomization&#xD;
&#xD;
          -  Angina precipitated by obvious provoking factors&#xD;
&#xD;
          -  Heart Failure defined as known ejection fraction less or equal to 40% or NYHA (New&#xD;
             York Heart Association) class III pr IV&#xD;
&#xD;
          -  Type I Diabetes Mellitus&#xD;
&#xD;
          -  Type II diabetes requiring insulin therapy&#xD;
&#xD;
          -  Hyperkaliemia&#xD;
&#xD;
          -  Acute chronic inflammatory, collagen tissue disease, auto-immune disease or cancer&#xD;
             and/or requiring the use of anti-inflammatory or anti-neoplastic agents at the time of&#xD;
             randomization&#xD;
&#xD;
          -  Use of a non-steriodal anti-inflammatory agent, coxibs, or anti-neoplasic agent within&#xD;
             last 7 days&#xD;
&#xD;
          -  Use of any oral or intra-venous steroidal agent in the last 7 days before study entry&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Systolic pressure &lt; 100 mmHg at randomization&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the protocol&#xD;
&#xD;
          -  Treatment with any investigational product or device in the last 4 weeks&#xD;
&#xD;
          -  Previous participation into the trial&#xD;
&#xD;
          -  History of hypersensitivity, allergy, or intolerance to Angiotensin-Converting Enzyme&#xD;
             inhibitors.&#xD;
&#xD;
          -  Severe cardiovascular diseases requiring urgent therapy&#xD;
&#xD;
          -  Severe or co-morbid condition&#xD;
&#xD;
          -  History of cancer not known to be disease free, with the exception of basal cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  Clinically important systemic disorder&#xD;
&#xD;
          -  Impaired hepatic function&#xD;
&#xD;
          -  Clinically important chronic or acute renal failure&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stan Glezer</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

